109 related articles for article (PubMed ID: 6763540)
1. Cyclosporin A as a tool for experimental and clinical transplantation.
Tutschka PJ
Biomed Pharmacother; 1982; 36(8-9):341-4. PubMed ID: 6763540
[TBL] [Abstract][Full Text] [Related]
2. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
Vossen J
Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
[TBL] [Abstract][Full Text] [Related]
4. [Cyclosporin A--a new immunosuppressive drug].
Towpik E; Araujo JL; Kupiec-Wegliński J; Tilney NL
Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1735-9. PubMed ID: 6395123
[No Abstract] [Full Text] [Related]
5. Effects of cyclosporin A on experimental graft-versus-host disease in rodents.
van Bekkum DW; Knaan S; Zurcher C
Transplant Proc; 1980 Jun; 12(2):278-82. PubMed ID: 6994295
[No Abstract] [Full Text] [Related]
6. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A and the immune response to transplantation antigens.
Hess AD
Lymphokine Res; 1982; 1(2):23-7. PubMed ID: 6239956
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin in bone marrow transplantation.
Atkinson K
Bone Marrow Transplant; 1987 Feb; 1(3):265-70. PubMed ID: 3332137
[TBL] [Abstract][Full Text] [Related]
10. Composite vascularized skin/bone transplantation models for bone marrow-based tolerance studies.
Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Siemionow M
Ann Plast Surg; 2006 Mar; 56(3):295-300. PubMed ID: 16508361
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of the acute graft versus host skin reaction with cyclosporin and PUVA].
Read D; Piérad GE; de la Brassinne M; Bury J
Ann Dermatol Venereol; 1988; 115(4):427-31. PubMed ID: 3046456
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporin-A prophylactic treatment of graft-versus-host disease in human allogeneic bone marrow transplantation: preliminary results.
Gluckman E; Arcese W; Devergie A; Boiron M
Transplant Proc; 1981 Mar; 13(1 Pt 1):368-70. PubMed ID: 7022855
[No Abstract] [Full Text] [Related]
13. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.
Tutschka PJ; Beschorner WE; Allison AC; Burns WH; Santos GW
Nature; 1979 Jul; 280(5718):148-51. PubMed ID: 45208
[No Abstract] [Full Text] [Related]
14. [New immunosuppressive agents].
Socié G; Thervet E
Pathol Biol (Paris); 1999 Oct; 47(8):827-35. PubMed ID: 10573703
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A.
Morris PJ
Transplantation; 1981 Nov; 32(5):349-54. PubMed ID: 6460358
[No Abstract] [Full Text] [Related]
16. Cyclosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs.
Deeg HJ; Storb R; Weiden PL; Graham T; Atkinson K; Thomas ED
Transplant Proc; 1981 Mar; 13(1 Pt 1):402-4. PubMed ID: 7022862
[No Abstract] [Full Text] [Related]
17. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
[TBL] [Abstract][Full Text] [Related]
18. Free bone graft attenuates acute rejection and in combination with cyclosporin a leads to indefinite cardiac allograft survival.
Wang H; Ge W; Arp J; Zassoko R; Liu W; Ichim TE; Jiang J; Jevnikar AM; Garcia B
J Immunol; 2009 May; 182(10):5970-81. PubMed ID: 19414748
[TBL] [Abstract][Full Text] [Related]
19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
20. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
